IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.190
+0.005 (0.42%)
Aug 27, 2026, 9:35 AM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,037,056
Market Cap
11.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 18 | 0 | - |
| Mar 31, 2026 | 18 | 0 | - |
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Daré Bioscience | 24 |
| BioLineRx | 24 |
| Moleculin Biotech | 17 |
| Theriva Biologics | 16 |
| Kiora Pharmaceuticals | 13 |
INAB News
- 20 days ago - IN8bio reports Q2 EPS (25c), consensus (37c) - TheFly
- 21 days ago - IN8bio Quarterly report: Q2 2026 - Filings
- 21 days ago - IN8bio Earnings release: Q2 2026 - Filings
- 7 weeks ago - IN8bio therapy doubles progression free survival in brain cancer trial - TheFly
- 7 weeks ago - IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 3 months ago - IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies - GlobeNewsWire
- 3 months ago - IN8bio Slides: Corporate presentation - Filings
- 3 months ago - IN8bio announces updated INB-200, INB-400 study data - TheFly